PDS Biotechnology Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PDSB research report →
About the company
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates.
- CEO
- Frank K. Bedu-Addo
- IPO
- 2015
- Employees
- 24
- HQ
- Princeton, NJ, US
Price Chart
- Market Cap
- $47.62M
- P/E
- -1.27
- P/S
- 0.00
- P/B
- 12.16
- EV/EBITDA
- -1.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -346.03%
- ROIC
- -146.60%
- Revenue
- $0 · 0.00%
- Net Income
- $-34,495,505 · 8.28%
- EPS
- $-0.74 · 28.16%
- Op Income
- $-31,543,959
- FCF YoY
- -79057.52%
- 52W High
- $1.55
- 52W Low
- $0.51
- 50D MA
- $1.05
- 200D MA
- $0.91
- Beta
- 1.56
- Avg Volume
- 1.03M
Get TickerSpark's AI analysis on PDSB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 12, 26 | BEDU-ADDO FRANK | other | 548,782 |
| Jan 12, 26 | CONN GREGORY | other | 150,000 |
| Jan 12, 26 | Shepard Kirk V. | other | 300,000 |
| Jan 12, 26 | Boesgaard Lars | other | 300,000 |
| Jan 12, 26 | Brown Spencer D. | other | 300,000 |
| Jan 12, 26 | Toutain Stephan | other | 300,000 |
| Jan 12, 26 | Freitag Gregory Gene | other | 54,876 |
| Jan 12, 26 | Iliev Ilian | other | 54,876 |
| Jan 12, 26 | Ali-Jackson Kamil | other | 54,876 |
| Jan 12, 26 | BRAWLEY OTIS W | other | 54,876 |
Our PDSB coverage
Recent articles, reports, and earnings notes.
No research on PDSB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PDSB report →Similar companies
Peers in the same neighborhood.